Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer

References

• Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control.2008;20:525–31.
   Google Scholar
• SEER Stat Fact Sheets: Thyroid [Internet]. Available from: http://seer.cancer.gov/statfacts/html/thyro.html (accessed 14 August 2013).
   Google Scholar
• ; The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerCooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167–214.
   Google Scholar
• Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7.
   Google Scholar
• Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111:508–16.
   PubMed Web of Science ®Google Scholar
• Yoo F, Chaikhoutdinov I, Mitzner R, Liao J, Goldenberg D. Characteristics of incidentally discovered thyroid cancer. JAMA Otolaryngol Head Neck Surg. 2013;139:1181–6.
   Google Scholar
• Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic Value of [18F]Fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–13.
   PubMed Web of Science ®Google Scholar
• Wu C-W, Dionigi G, Lee K-W, Hsiao P-J, Paul Shin M-C, Tsai K-B, et al. Calcifications in thyroid nodules identified on preoperative computed tomography: patterns and clinical significance. Surgery. 2012;151: 464–70.
   Google Scholar
• Kim BK, Choi YS, Kwon HJ, Lee JS, Heo JJ, Han YJ, et al. Relationship between patterns of calcification in thyroid nodules and histopathologic findings. Endocr J. 2013;60:155–60.
   PubMed Web of Science ®Google Scholar
• Lee JH, Jeong SY, Kim YH. Clinical significance of incidental thyroid nodules identified on low-dose CT for lung cancer screening. Multidiscip Respir Med. 2013;8:56.
   Google Scholar
• Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid Off J Am Thyroid Assoc. 2012;22:918–25.
   Google Scholar
• Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005;237:794–800.
   PubMed Web of Science ®Google Scholar
• Sheth S. Role of ultrasonography in thyroid disease. Otolaryngol Clin North Am. 2010;43:239–55, vii.
   Google Scholar
• Hong YJ, Son EJ, Kim E-K, Kwak JY, Hong SW, Chang H-S. Positive predictive values of sonographic features of solid thyroid nodule. Clin Imaging. 2010;34:127–33.
   Google Scholar
• Moon W-J, Jung SL, Lee JH, Na DG, Baek J-H, Lee YH, et al. Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study. Radiology. 2008;247:762–70.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.
   PubMed Web of Science ®Google Scholar
• Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668–73.
   PubMed Web of Science ®Google Scholar
• Intenzo CM, Dam HQ, Manzone TA, Kim SM. Imaging of the thyroid in benign and malignant disease. Semin Nucl Med. 2012;42: 49–61.
   Google Scholar
• Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? [Internet]. 2002. Available from: http://press.endocrine.org/doi/full/10.1210/jcem.87.7.8702 (accessed 16 March 2014).
   Google Scholar
• Park E-K, Chung J-K, Lim IH, Park DJ, Lee DS, Lee MC, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging. 2009;36:172–9.
   Google Scholar
• Oh J-R, Byun B-H, Hong S-P, Chong A, Kim J, Yoo S-W, et al. Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38:1459–68.
   Google Scholar
• Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547–52.
   PubMedGoogle Scholar
• Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–42.
   PubMedGoogle Scholar
• Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. Am J Roentgenol. 2008;191: 1785–94.
   PubMedGoogle Scholar
• Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1952–7.
   PubMedGoogle Scholar
• Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endocrinol Metab. 2012;26:83–96.
   Google Scholar
• Cibas ES, Ali SZ; NCI Thyroid FNA State of the Science Conference. The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658–65.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569–80.
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184–99.
   PubMed Web of Science ®Google Scholar
• Keutgen XM, Filicori F, Fahey TJ. Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev Mol Diagn. 2013;13:613–23.
   PubMed Web of Science ®Google Scholar
• Yip L. Molecular diagnostic testing and the indeterminate thyroid nodule. Curr Opin Oncol. 2014;26:8–13.
   Google Scholar
• Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53–62.
   PubMed Web of Science ®Google Scholar
• Goyal N, Setabutr D, Abdulghani J, Goldenberg D. Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. In: El-Deiry WS, editor. Impact of genetic targets on cancer therapy [Internet]. New York, NY: Springer New York; 2013. p. 309–26. Available from: http://www.springerlink.com/index/10.1007/978-1-4614-6176-0_14 (accessed 23 October 2013).
   Google Scholar
• Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D’Cruz A, Rajan MGR. BRAF V600E Mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. 2011;23:83–93.
   Google Scholar
• Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAFV600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;16:240–5.
   Google Scholar
• Kim S, Lee KE, Myong JP, Park J, Jeon YK, Min HS, et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2011;36:310–17.
   Google Scholar
• Zhou Y-L, Zhang W, Gao E-L, Dai X-X, Yang H, Zhang X-H, et al. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac J Cancer Prev. 2012;13:1267–72.
   Google Scholar
• Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer. 2009;115:972–80.
   PubMed Web of Science ®Google Scholar
• Joo J-Y, Park J-Y, Yoon Y-H, Choi B, Kim J-M, Jo YS, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab. 2012;97:3996–4003.
   Google Scholar
• Wang W, Zhao W, Wang H, Teng X, Wang H, Chen X, et al. Poorer prognosis and higher prevalence of BRAF V600E mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol. 2011; 19:31–6.
   Google Scholar
• Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol. 2012;20:47–52.
   Google Scholar
• Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope. 2012;122:1634–40.
   Google Scholar
• Takahashi M, Cooper GM. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol. 1987;7: 1378–85.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13:3–16.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42:581–8.
   PubMed Web of Science ®Google Scholar
• Castellone MD, Santoro M. Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:363–74.
   PubMed Web of Science ®Google Scholar
• Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306.
   PubMed Web of Science ®Google Scholar
• Sheils OM, O'eary JJ, Uhlmann V, Lättich K, Sweeney EC. ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol. 2000;8:185–9.
   PubMedGoogle Scholar
• De Vries MM, Celestino R, Castro P, Eloy C, Máximo V, van der Wal JE, et al. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. Histopathology. 2012;61:833–43.
   PubMed Web of Science ®Google Scholar
• Kroll TG, Sarraf P, Pecciarini L, Chen C-J, Mueller E, Spiegelman BM, et al. PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science. 2000;289:1357–60.
   PubMed Web of Science ®Google Scholar
• Eberhardt NL, Grebe SKG, McIver B, Reddi HV. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321:50–6.
   PubMedGoogle Scholar
• Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002 Aug;26(8):1016–23.
   Google Scholar
• Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002 Aug;87(8):3947–52.
   Google Scholar
• Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jan;91(1):213–20.
   Google Scholar
• Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50:529–35.
   PubMed Web of Science ®Google Scholar
• Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990;4:1474–9.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17–44.
   PubMed Web of Science ®Google Scholar
• Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 1993;91: 1753–60.
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T, et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol Am J Surg Pathol Part B. 1994;3:9–14.
   PubMedGoogle Scholar
• Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler M-P, Allou L, et al. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology (Phila). 2011;43: 447–52.
   Google Scholar
• Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98: E1852–60.
   PubMed Web of Science ®Google Scholar
• Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113:2440–7.
   PubMed Web of Science ®Google Scholar
• García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJA, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199–207.
   PubMed Web of Science ®Google Scholar
• Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20:697–706.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007;92:2387–90.
   PubMedGoogle Scholar
• Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005;90:4688–93.
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–62.
   PubMed Web of Science ®Google Scholar
• Pacini F. Thyroid function: optimizing molecular testing in thyroid nodule cytology. Nat Rev Endocrinol. 2012;8:390–1.
   Google Scholar
• Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP, Seethala RR, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol. 2010;118:17–23.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96:3390–7.
   PubMed Web of Science ®Google Scholar
• Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365–9.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092–8.
   PubMed Web of Science ®Google Scholar
• Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung B-M, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010;34:2589–94.
   PubMed Web of Science ®Google Scholar
• Yip L, Farris C, Kabaker AS, Hodak SP, Nikiforova MN, McCoy KL, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab. 2012;97:1905–12.
   PubMed Web of Science ®Google Scholar
• Thyroid cancer diagnosis [Internet]. Asuragen. Available from: http://asuragen.com/products-and-services/clinical-lab/mirinform-thyroid/ (accessed 7 March 2014).
   Google Scholar
• Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, et al. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol. 2010;118:287–97.
   Google Scholar
• Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010;95:5296–304.
   PubMed Web of Science ®Google Scholar
• Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.
   PubMed Web of Science ®Google Scholar
• Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LGT, Liang Y, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013;98:E962–72.
   Web of Science ®Google Scholar
• Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, et al. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014;99:119–25.
   PubMed Web of Science ®Google Scholar
• Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid Off J Am Thyroid Assoc. 2012 Oct;22(10):996–1001.
   Google Scholar
• Wiseman SM, Haddad Z, Walker B, Vergara IA, Sierocinski T, Crisan A, et al. Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosis. J Clin Endocrinol Metab. 2013;98:4072–9.
   PubMed Web of Science ®Google Scholar
• Lodewijk L, Prins AM, Kist JW, Valk GD, Kranenburg O, Rinkes IHMB, et al. The value of miRNA in diagnosing thyroid cancer: a systematic review. Cancer Biomark Sect Dis Markers. 2012;11:229–38.
   Google Scholar
• Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab. 2013;98:E1–7.
   PubMed Web of Science ®Google Scholar
• Stokowy T, Wojtaś B, Fujarewicz K, Jarząb B, Eszlinger M, Paschke R. miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis. Horm Metab Res. 2014;46:171–80.
   Google Scholar
• Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:2032–8.
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9:543–9.
   PubMed Web of Science ®Google Scholar
• Raggio E, Camandona M, Solerio D, Martino P, Franchello A, Orlandi F, et al. The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest. 2010;33:378–81.
   PubMedGoogle Scholar
• Franco C, Martínez V, Allamand JP, Medina F, Glasinovic A, Osorio M, et al. Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol. 2009;17: 211–15.
   PubMedGoogle Scholar
• De Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97.
   PubMed Web of Science ®Google Scholar
• Yang X, Wu Z, Xiao J, Teng H, Feng D, Huang W, et al. Sequentially Staged Resection and 2-Column Reconstruction for C2 Tumors Through a Combined Anterior Retropharyngeal-Posterior Approach: Surgical Technique and Results in 11 Patients. Neurosurg Dec 2011 [Internet]. 2011 [cited 2014 Apr 27];Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=ovftm&AN=00006123-201112002-00008.
   Google Scholar
• Lacoste-Collin L, d’Aure D, Bérard E, Rouquette I, Delisle MB, Courtade-Saïdi M. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls. Cytopathology. 2014;n/a–n/a.
   Google Scholar
• Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005 Apr 14;434(7035):843–50.
   PubMedGoogle Scholar
• Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A, et al. beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol. 2004;15(4):329–37.
   Google Scholar
• Aragon Han P, Olson MT, Fazeli R, Prescott JD, Pai SI, Schneider EB, et al. The Impact of Molecular Testing on the Surgical Management of Patients with Thyroid Nodules. Ann Surg Oncol. 2014 Feb 13.
   Google Scholar
• Harrell RM, Bimston DN. Surgical Utility of Afirma: Effects of High Cancer Prevalence and Oncocytic Cell Types in Patients with Indeterminate Thyroid Cytology. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2013 Nov 18;1–16.
   Google Scholar
• Hodak SP, Rosenthal for the American Thyroid DS. Information for Clinicians: Commercially Available Molecular Diagnosis Testing in the Evaluation of Thyroid Nodule Fine-Needle Aspiration Specimens. Thyroid. 2013 Feb;23(2):131–4.
   Google Scholar